アブストラクト
| Title | No.4 副作用管理 : 免疫関連有害事象 (irAE) |
|---|---|
| Subtitle | シリーズ 抗がん薬治療の副作用 |
| Authors | 池末裕明 |
| Authors (kana) | |
| Organization | 神戸市立医療センター中央市民病院薬剤部 |
| Journal | 日本臨床腫瘍薬学会雑誌 |
| Volume | 17 |
| Number | |
| Page | 11-19 |
| Year/Month | 2020 / 10 |
| Article | 報告 |
| Publisher | 日本臨床腫瘍薬学会 |
| Abstract | 「POINT」・irAEの特徴を理解する. ・irAE発現時の標準的な対応を理解する. ・多様な組織に発現するため, 早期発見の重要性を理解する. 「はじめに」これまでがん薬物療法は, 主に細胞障害性抗がん薬, 分子標的薬およびホルモン療法が用いられてきた. 免疫チェックポイント阻害薬は, これらの薬剤とは異なる新たな作用機序を有する抗がん薬であり, 既に多くのがん種で効果が認められている. 一方, 安全性の面では, 従来型の抗がん薬とは機序の異なる免疫関連有害事象(immune-related adverse event:irAE)が発現する可能性がある. 従来型の細胞障害性抗がん薬では, 抗がん薬の種類によって有害事象の種類や発現時期に特徴があり, このためレジメン毎にいつ, いかなる有害事象に注意すべきか事前に予測し, 対策を講じることが有用である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 池末裕明, 他 : がん化学療法ワークシート第5版 : じほう, 2020年4月.
- 2) Leach DR, Krummel MF, Allison JP : Enhancement of antitumor immunity by CTLA-4 blockade, Science 1996 ; 271(5256) : 1734-1736.
- 3) Nishimura H, Nose M, Hiai H, Minato N, Honjo T : Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity 1999 ; 11(2) : 141-151.
- 4) Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Frontera OA, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR : Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med 2015 ; 373(2) : 123-135.
- 5) Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR : Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med 2015 ; 373(17) : 1627-1639.
残りの26件を表示する
- 6) Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr., Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA ; CheckMate 026 Investigators : CheckMate 026 Investigators : First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med 2017 ; 376(25) : 2415-2426.
- 7) 日本臨床腫瘍学会 : がん免疫療法ガイドライン第2版 : 金原出版, 2019年3月.
- 8) Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA ; National Comprehensive Cancer Network : ASCO management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol 2018 ; 36(17) : 1714-1768.
- 9) Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K ; ESMO Guidelines Committee : Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol 2017 ; 28(suppl 4) : iv119-iv142.
- 10) National Comprehensive Cancer Network : Management of immunotherapy-related toxicities. version 1. 2020.(https://www.nccn.org)
- 11) Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS ; Society for Immunotherapy of Cancer Toxicity Management Working Group : Managing toxicities associated with immune checkpoint inhibitors : consensus recommendations from the Society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group, J Immunother Cancer 2017 ; 5(1) : 95.
- 12) Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS : Nivolumab in resected and unresectable metastatic melanoma : characteristics of immune-related adverse events and association with outcomes, Clin Cancer Res 2016 ; 22(4) : 886-894.
- 13) Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K : Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab : a prospective cohort study, J Thorac Oncol 2017 ; 12(12) : 1798-1805.
- 14) Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K : Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer, JAMA Oncol 2018 ; 4(3) : 374-378.
- 15) Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR : Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors : a systematic review, Ann Oncol 2017 ; 28(10) : 2377-2385.
- 16) Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M : Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance, Nat Rev Clin Oncol 2019 ; 16(9) : 563-580.
- 17) Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD : Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med 2015 ; 373(1) : 23-34.
- 18) Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B ; CheckMate 214 Investigators : CheckMate 214 Investigators : Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med 2018 ; 378(14) : 1277-1290.
- 19) 里内美弥子, 他 : 免疫チェックポイント阻害薬と関連する重症の皮疹および粘膜疹の検討と, 多職種による皮膚障害発現抑止を企図した早期介入システム構築の試行-第5回皮膚科・腫瘍内科有志コンセンサス会議の報告-, 臨床医薬 2018 ; 34 : 405-419.
- 20) Kato T, Masuda N, Nakanishi Y, Takahashi M, Hida T, Sakai H, Atagi S, Fujita S, Tanaka H, Takeda K, Satouchi M, Namba Y, Tamura T : Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer, Lung Cancer 2017 ; 104 : 111-118.
- 21) Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V : Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer : a systematic review and meta-analysis of trials, Chest 2017 ; 152(2) : 271-281.
- 22) Kotake M, Murakami H, Kenmotsu H, Naito T, Takahashi T : High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy, Ann Oncol 2017 ; 28(3) : 669-670.
- 23) Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F : Enterocolitis due to immune checkpoint inhibitors : a systematic review, Gut 2018 ; 67(11) : 2056-2067.
- 24) Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y : Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis, J Immunother Cancer 2019 ; 7(1) : 93.
- 25) Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C : Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat Rev 2017 ; 58 : 70-76.
- 26) 日本内分泌学会 : 免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン, 日本内分泌学会雑誌 2018 ; 94(S. November) : 1-11.
- 27) Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD : Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann Oncol 2017 ; 28(3) : 583-589.
- 28) Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y : Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab, Cancer Sci 2018 ; 109(11) : 3583-3590.
- 29) 各務博, 他 : チームで取り組む免疫チェックポイント阻害薬治療 : 中外医学社, 2019年10月.
- 30) 中西洋一, 他 : 対応の流れと治療のポイントがわかるフローチャート抗がん薬副作用 : じほう, 2020年3月.
- 31) Ikesue H, Kusuda K, Satsuma Y, Nishiwaki F, Miura R, Masuda Y, Hirabatake M, Muroi N, Fujimoto D, Morimoto T, Tomii K, Hashida T : Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer, J Clin Pharm Ther 2020 ; Epub ahead of print.
